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A20 is a ubiquitin modifying enzyme that restricts
NF-kB signals and protects cells against tumor
necrosis factor (TNF)-induced programmed cell
death. Given recent data linking A20 (TNFAIP3) with
human B cell lymphomas and systemic lupus erythe-
matosus (SLE), we have generated mice bearing
a floxed allele of Tnfaip3 to interrogate A20’s roles
in regulating B cell functions. A20-deficient B cells
are hyperresponsive to multiple stimuli and display
exaggerated NF-kB responses to CD40-induced
signals. Mice expressing absent or hypomorphic
amounts of A20 in B cells possess elevated numbers
of germinal center B cells, autoantibodies, and
glomerular immunoglobulin deposits. A20-deficient
B cells are resistant to Fas-mediated cell death, prob-
ably due to increased expression of NF-kB-depen-
dent antiapoptoticproteins suchasBcl-x. Thesefind-
ings show that A20 can restrict B cell survival,
whereas A20 protects other cells from TNF-induced
cell death. Our studies demonstrate how reduced
A20 expression predisposes to autoimmunity.
INTRODUCTION
Maintenance of B cell homeostasis requires proper intracellular
integration of signals delivered from multiple surface receptors
such as the B cell antigen receptor, Toll-like receptors (TLRs),
B cell-activating factor (BAFF) receptor, and CD40, as well as
intracellular cues. Failure to integrate pathways such as NF-kB
signaling can lead to B cell deficiency, aberrant B cell activity,
or even lymphoma. Aberrant B cell tolerance and selection can
cause production of autoantibodies, formation of immune
complexes (IC), and ultimately tissue damage and autoimmune
disease (Fairhurst et al., 2006).
Tnfaip3 encodes the A20 protein, a ubiquitin-modifying
enzyme (Wertz et al., 2004; Boone et al., 2004). A20 was initially
identified as a TNF-induced molecule that restricts TNF inducedsignaling (Opipari et al., 1990). Targeting of Tnfaip3 in mice re-
vealed A20s critical anti-inflammatory functions, given that
A20-deficient (Tnfaip3/) mice exhibit severe spontaneousmul-
tiorgan inflammation, cachexia, and perinatal death (Lee et al.,
2000). Epistasis experiments revealed that A20 restricts TLR
and nucleosome-binding oligomerization domain (NOD) trig-
gered NF-kB signaling, in addition to TNF-induced NF-kB and
programmed cell death (PCD) signaling (Lee et al., 2000; Boone
et al., 2004; Hitotsumatsu et al., 2008). Thus, A20 restricts
a number of innate immune signaling pathways in macrophages
and fibroblasts. The severe systemic inflammation and cachexia
caused by A20 deficiency is ameliorated in mice that also lack
the TLR adaptor protein MyD88 (Turer et al., 2008). Radiation
chimeras bearing Tnfaip3/ hematopoietic cells also develop
spontaneous systemic inflammation, which is alleviated by
depletion of commensal intestinal bacteria with antibiotics (Turer
et al., 2008). Thus, A20 maintains immune homeostasis and
restricts the potentially proinflammatory nature of basal
MyD88-dependent signals.
In addition to the innate immune functions described above in
macrophages and fibroblasts, A20 is also expressed in T and B
cells (Sarma et al., 1995; Lee et al., 2000). During T cell activation,
A20 is recruited to the MALT-1-Bcl-10 scaffold complex, and is
cleaved by the paracaspase MALT-1 (Coornaert et al., 2008).
A20 has also been reported to deubiquitinate MALT-1 to restrict
TCR signals (Du¨wel et al., 2009). A20 cleavage is also observed
in B lymphoma cell lines in response to BCR stimulation (Coor-
naert et al., 2008). Other clues that A20 may play important roles
in adaptive lymphocytes derives from human genetic studies
that implicate A20 (or TNFAIP3) as a susceptibility gene for
systemic lupus erythematosus (SLE)—an autoimmune disease
associated with aberrant B cell function—as well as studies
showing that A20 is a tumor suppressor in B cell lymphomas
(Graham et al., 2008; Musone et al., 2008; Compagno et al.,
2009; Kato et al., 2009; Novak et al., 2009; Schmitz et al.,
2009). Nevertheless, the physiological roles of A20 in T and B
cells are largely undefined.
B cells are regulated by BCR, TLR, BAFF, and CD40 signals.
These signaling cascades share some of the same ubiquitin-
dependent signaling molecules utilized by TNF and TLR ligands
(e.g., TRAF2, TRAF6, IKKg) (Hayden and Ghosh, 2008). Given
A20’s role in preventing inflammation, its genetic linkage toImmunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc. 181
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Figure 1. Gene Targeting Strategy to
Generate Mice Lacking Tnfaip3 in B Cells
(A) Schematic representation of the gene targeting
construct and screening strategy for obtaining the
Tnfaip3 floxed (fl) allele. Half arrows indicate
locations of PCR primers for distinguishing wild-
type (+), floxed (fl), and deleted (del) alleles.
(B) Southern blots of BamHI-digested genomic
DNA from ESCs showing the targeted allele (left
blot) and from tails from mice with germline
inheritance of the fl allele (right blot).
(C) Genomic DNA PCR analysis of wild-type (+),
floxed (fl), and deleted (del) alleles of Tnfaip3
exon 2 in the indicated cell types from mice of
the indicated genotypes with PCR primers shown
in (A). BMDMs are bone marrow-derived macro-
phages. All mice are CD19-Cre+/. PCR products
for floxed (fl), wild-type (+), and deleted (del) alleles
are indicated. Data are representative of five mice
per genotype.
(D) Quantitative genomic DNA PCR analysis of
Tnfaip3 exon 2 in flow cytometry-sorted popula-
tions of immature (CD19+ CD93[AA4.1]+) and GC
(CD19+ GL7+ CD95+) B cells from mice of the indi-
cated genotypes. PCR primers are described in
the Experimental Procedures. Error bars show
SEM of three mice per genotype.
(E) Immunoblot analysis of A20 expression in B
cells from the indicated genotypes of mice. The
A20 to actin protein ratio relative to Tnfaip3+/+
CD19-Cre cells is shown below the blots.
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A20 Restricts B Cell Survivalhuman B cell lymphomas and SLE, and the central role B cells
play in SLE pathogenesis, we hypothesized that A20 may regu-
late B cell homeostasis and prevent autoimmunity. To determine
the cell intrinsic functions of A20 in regulating B cells, we have
generated mice lacking A20 specifically in these cells.
RESULTS
B-Lineage Deletion of A20 Perturbs
Lymphoid Homeostasis
In order to analyze the cell intrinsic functions of A20 in B cells, we
generated a targeting construct in which exon 2 of the Tnfaip3
gene was flanked by loxP sites, a ‘‘floxed’’ allele. The targeting
construct was transfected into C57BL/6 ES cells and neomycin
resistant clones were screened for the targeted allele (Figures
1A and 1B). Transient transfection of Cre recombinase resulted
in removal of the neomycin cassette to obtain the floxed Tnfaip3
allele (Figures 1A and 1B). ES clones were injected into albino
C57BL/6 blastocysts, and the resultant chimeras were bred182 Immunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc.with albino C57BL/6 mice. Non-albino
C57BL/6 progeny were screened for the
presence of the floxed allele, Tnfaip3fl
(Figure 1B).
Mice carrying the Tnfaip3fl allele were
bred with Cd19-Cre knock-in mice for
generation of Tnfaip3+/+, Tnfaip3fl/+ and
Tnfaip3fl/fl mice bearing a single copy of
the CD19-Cre allele (Rickert et al., 1997).
All mice described in this study wereheterozygous for the CD19-Cre targeted allele (CD19-Cre+/) to
control for potential nonspecific effects of Cre expression while
maintaining CD19 expression. For simplicity, CD19-Cre+/ mice
will subsequently be referred to as CD19-Cre mice. As has
been found for other ‘‘floxed’’ alleles, Tnfaip3fl/fl CD19-Cre mice
had efficient and B cell-specific deletion of Tnfaip3 exon 2, as as-
sessed by genomic polymerase chain reaction (PCR) and
Southern blotting (Figure 1C and data not shown). Flow cytome-
try-sorted immature and germinal center (GC) B cells, subsets
represented in smaller proportions, were also nearly 100%
deleted as measured by quantitative genomic PCR (Figure 1D).
A20 protein is constitutively expressed in B cells and T cells
(Figure 1E and data not shown). Deletion of tnfaip3 exon 2 on
both alleles (Tnfaip3fl/fl CD19-Cre) led to complete loss of A20
protein in splenic B cells (Figure 1E). Note that deletion of one
allele of tnfaip3 in Tnfaip3fl/+ CD19-Cre mice causes hypomor-
phic (50%) expression of A20 protein in B cells (Figure 1E).
Tnfaip3fl/fl CD19-Cre mice were obtained in Mendelian
numbers and developed normally. Hence, these mice differed
Table 1. Cellularity of Lymphoid Organs and Respective
Subpopulations in Tnfaip3fl CD19-Cre Mice
Tnfaip3+/+ Tnfaip3fl/+ Tnfaip3fl/fl
Total Cellularity (3106)
Lymph nodes 14.3 ± 0.7 15.8 ± 1.2 25.7 ± 3.7*
Spleen 44.4 ± 11 55.4 ± 9.0 74.2 ± 11
Bone marrow 31.4 ± 3.2 30.7 ± 5.6 31.2 ± 4.1
Peritoneum 4.7 ± 0.7 3.8 ± 1.1 8.1 ± 1.6
Lymph Nodes (3106)
B cells 3.9 ± 0.2 4.7 ± 0.5 8.8 ± 1.1*
T cells 8.9 ± 0.7 8.4 ± 0.8 12.9 ± 1.6*
myeloid cells 0.15 ± 0.03 0.15 ± 0.03 0.24 ± 0.03
mature B cells 2.5 ± 0.1 2.9 ± 0.3 3.3 ± 0.5
immature B cells 1.2 ± 0.1 1.1 ± 0.2 3.9 ± 0.3*
germinal center B cells 0.01 ± 0.003 0.08 ± 0.02* 0.05 ± 0.02*
Spleen (3106)
B cells 23.7 ± 6.0 26.5 ± 4.5 37.8 ± 6.4
T cells 16.5 ± 0.8 16.1 ± 1.7 24.7 ± 2.5*
myeloid cells 0.7 ± 0.03 1.0 ± 0.2 1.4 ± 0.3
mature B cells 11.2 ± 1.4 15.1 ± 3.6 17.9 ± 3.1
immature B cells 9.8 ± 0.6 9.2 ± 0.7 14.8 ± 2.6*
germinal center B cells 0.17 ± 0.03 0.6 ± 0.15* 0.45 ± 0.08*
marginal zone B cells 1.6 ± 0.08 1.1 ± 0.3 0.9 ± 0.2
Peritoneum (3106)
B cells 1.6 ± 0.34 2.7 ± 0.25 4.1 ± 0.37
B1a 0.45 ± 0.04 0.69 ± 0.16 0.6 ± 0.24
B2 0.55 ± 0.16 0.93 ± 0.11 1.6 ± 0.12
Quantitation of lymphoid populations in the indicated tissues from the
indicated genotypes of 5- to 7-week-old mice. The total cellularity of
lymphoid organs is shown in the top panel. Subpopulations were identi-
fied by flow cytometry with the indicated markers: B cells (CD19+); T cells
(TCR-b+); myeloid cells (Mac-1+); mature B cells (CD19+, IgMLo, IgD+);
immature B cells (CD19+ IgMHi); marginal zone B cells (CD21/35Hi
CD23Lo); GC B cells (CD19+, GL7+, CD95+); and B1a (IgM+, CD5+). The
asterisk indicates significant difference relative to +/+ (p < 0.05, with
one-way ANOVA). For GC B cells, means are from five mice per geno-
type; for all other subpopulations, means of 5 Tnfaip3+/+ CD19-Cre,
11 Tnfaip3fl/+ CD19-Cre, and 11 Tnfaip3fl/fl CD19-Cre mice are shown.
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A20 Restricts B Cell Survivaldramatically frommice lacking A20 in all cells or in all hematopoi-
etic cells, both of which develop severe spontaneous inflamma-
tion and early lethality (Lee et al., 2000; Boone et al., 2004; Turer
et al., 2008). To begin to assess the roles of A20 in regulating B
cells, we quantitated lymphoid populations from 5- to 7-week-
old Tnfaip3fl/fl CD19-Cre, Tnfaip3fl/+ CD19-Cre and Tnfaip3+/+
CD19-Cre littermates by flow cytometry (Table 1, top panel).
Tnfaip3fl/fl CD19-Cre mice contained moderately increased
numbers of B cells (CD19+), particularly immature B cells
(CD19+IgMhi) and germinal center (GC) B cells, when compared
to Tnfaip3+/+ CD19-Cre control mice (Table 1, Figures 2A–2C).
Although the percentage of B1a (IgM+, CD5+) cells in the perito-
neal cavity of Tnfaip3fl/fl CD19-Cre mice was lower than
Tnfaip3+/+ CD19-Cre and Tnfaip3fl/+ CD19-Cre mice, the abso-
lute number was not significantly different (Figure S1A; Table 1).
Although A20 deletion in Tnfaip3fl/fl CD19-Cre mice occurs in B
cells and not T cells (Figure 1C), both B cells (CD19+) andT cells (TCR-b+) were modestly expanded in Tnfaip3fl/fl CD19-
Cre mice (Figure 2A and Table 1). The relative percentages of
T cell subpopulations (CD4+, CD8+, and T regulatory) were
normal (data not shown). Taken together, these findings suggest
that A20 restricts the numbers of B cells, particularly immature
and GC B cells.
Heterozygous Tnfaip3fl/+ CD19-Cre mice possess largely
normal numbers of lymphoid populations, even though
Tnfaip3fl/+ CD19-Cre B cells express half the amount of A20
protein as wild-type Tnfaip3+/+ CD19-Cre B cells (Figure 1E).
A notable exception is that the numbers of germinal center (GC)
(CD95+GL7+) B cells in Tnfaip3fl/+ CD19-Cremice approximates
the number present in Tnfaip3fl/fl CD19-Cremice (Figure 2C and
Table 1). Thus, proper regulation of GC B cell homeostasis
requires more A20 protein than other B cell populations.
Bone marrow from Tnfaip3fl/fl CD19-Cre and Tnfaip3fl/+ CD19-
Cre mice contained normal numbers of B lineage cells, with
normal proportions of pro-B (CD43+, IgM) and pre-B (CD43,
IgM) cells (Figure S1B). There was a small decrease in the
percentage of IgM+ B cells in Tnfaip3fl/fl CD19-Cre bone marrow,
which reflected reductions in mature or recirculating (IgM+, IgD+)
B cells (Figure S1B). As CD19 is expressed throughout B cell
development, these results suggest that A20 is not required for
early B cell differentiation.
The differences in peripheral lymphocyte populations
described above persisted but were not further exaggerated in
6-month-old mice (Figure S1C and data not shown). In addition,
6-month-old Tnfaip3fl/+CD19-Cre and Tnfaip3fl/flCD19-Cremice
contained increased percentages of splenic plasma cells when
compared to Tnfaip3+/+ CD19-Cre mice (Figure 2D). Whereas
markers of B cell activation were expressed normally in 5- to
7-week-old mice, spontaneous B cell activation became
apparent in 6-month-old Tnfaip3fl/fl CD19-Cre but not Tnfaip3fl/+
CD19-Cre mice (Figure 2E and Figure S1D). Spontaneous T cell
activation was not observed (data not shown). These findings
suggest that A20 expression in B cells prevents spontaneous
activation and differentiation of B cells over time.
Overall, elevated numbers of T and B cells and spontaneous B
cell activation were observed in Tnfaip3fl/fl CD19-Cre mice by 6
months of age. In addition, elevated numbers of GC B cells
were observed in both heterozygous Tnfaip3fl/+ CD19-Cre mice
and homozygous Tnfaip3fl/fl CD19-Cre mice.
Exaggerated Responses of Tnfaip3fl/fl CD19-Cre B Cells
In Vitro
Our prior work indicated that A20 restricts TNF-, TLR-, andNOD-
induced NF-kB signals as well as TNF-induced PCD in fibro-
blasts and macrophages (Lee et al., 2000; Boone et al., 2004;
Hitotsumatsu et al., 2008; Turer et al., 2008). B cells receive acti-
vation, proliferation, and survival signals from BCR, CD40
receptor, and other receptors (Skaug et al., 2009). To test
whether A20 directly regulates B cell responses, we assayed
responses of Tnfaip3fl/fl CD19-Cre, Tnfaip3fl/+ CD19-Cre, and
Tnfaip3+/+ CD19-Cre splenic B cells to LPS, cytosine phospho-
guanine oligodeoxynucleotide (CpG) and to agonist anti-IgM
and anti-CD40. As noted above, unstimulated splenic B cells
from young (5- to 7-week-old) Tnfaip3fl/fl CD19-Cremice resem-
bled B cells from Tnfaip3fl/+ CD19-Cre and Tnfaip3+/+ CD19-Cre
mice (Figure S1D). Tnfaip3fl/flCD19-CreB cells expressed higherImmunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc. 183
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Figure 2. Flow Cytometric Analyses of B Lymphocyte Populations in Tnfaip3fl/fl CD19-Cre Mice
Flow cytometric analyses of lymphoid tissues.
(A) Analyses of lymphoid populations in spleens and peripheral lymph nodes from 5- to 7-week-old mice.
(B) Analysis of CD19+ gated cells showing B cell maturation (IgM, IgD) from 5- to 7-week-old mice.
(C) Analysis of CD19+ gated cells showing GC B cells (GL7+ CD95+) from 5- to 7-week-old mice.
(D) Plasma cells (CD19+ low CD138+) within TCR-bCD19+ gated splenic B cells from 6-month-oldmice are shown. Percentages of cells within the indicated gates
are shown on plots (A–D).
(E) Histograms comparing expression of B cell activation markers (CD80, CD69, and CD95) on CD19+ gated B cells from 6-month-old mice: Tnfaip3+/+ (shaded
histogram), Tnfaip3fl/+ (blue line), and Tnfaip3fl/fl (red line). All data compare littermates of the indicated genotypes and are representative of three to five mice per
genotype.
Immunity
A20 Restricts B Cell Survivalamounts of CD80 (B7.1) and CD69 after stimulation with several
B cell agonists (Figure 3 and data not shown). Tnfaip3fl/fl CD19-
Cre B cells also proliferated to a greater extent than control cells
(Figure 3B). Third, Tnfaip3fl/fl CD19-Cre B cells produced more
IL-6 than Tnfaip3fl/+ CD19-Cre and Tnfaip3+/+ CD19-Cre cells
after treatment with LPS and CpG (Figure 3C).
To control for potential differences in B cell populations and to
avoid potential caveats associated with developmental abnor-
malities, we sought to eliminate A20 expression in mature B cells
after B cell development. Accordingly, we interbred Tnfaip3fl
mice with estrogen receptor (ER)-Cre [Gt(ROSA)26ER-Cre]
mice to obtain mice in which A20 (Tnfaip3) deletion would
not occur until cells were exposed to 4-hydroxytamoxifen
(4-OH-T). Splenic B cells enriched from Tnfaip3fl/fl ER-Cre mice
and treated with 4-OH-T in vitro effectively ablated A20 protein
expression (Figure 3D). We then tested responses of these B
cells. Consistent with our findings with Tnfaip3fl/fl CD19-Cre B
cells, mature splenic Tnfaip3fl/fl ER-Cre B cells rendered acutely
A20 deficient with 4-OH-T exhibited exaggerated responses to184 Immunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc.all receptor stimuli when compared to control Tnfaip3fl/+ ER-Cre
cells (Figure 3E). Thus, A20 expression in mature B cells restricts
B cell responses independently of any potential roles of A20 in
regulating B cell development.
A20 Restricts NF-kB Activation Signals Downstream
of CD40
A20 restricts cellular responses to TNF, TLR, and NOD2 ligands
by restricting NF-kB signaling (Lee et al., 2000; Boone et al.,
2004; Hitotsumatsu et al., 2008; Turer et al., 2008). CD40 is
a tumor necrosis factor receptor (TNFR) family member that trig-
gers NF-kB signals and supports B cell activation and survival
(Elgueta et al., 2009). To test whether A20 directly restricts
CD40-induced NF-kB signals, we stimulated splenic B cells
from Tnfaip3+/+ CD19-Cre and Tnfaip3fl/fl CD19-Cre mice with
agonist anti-CD40 antibody. A20 protein was dramatically
induced by CD40 engagement in Tnfaip3+/+ CD19-Cre B cells,
whereas no A20 expression was observed in Tnfaip3fl/fl CD19-
Cre B cells (Figure 4). Tnfaip3fl/fl CD19-Cre B cells displayed
Media IL-4 α−CD40
α−CD40
+ IL-4LPS α−μ
CD80
Actin
A20
fl/+ fl/fl
Media IL-4 α−CD40
α−CD40
+ IL-4LPSα−μ
fl/+ fl/fl fl/+ fl/fl fl/+ fl/fl fl/+ fl/fl fl/+ fl/fl
CD80
α−CD40 α−CD40
+ IL-4
LPS α−μ
CpG
CFSE
0
250
500
750
1000
IL
-6
 (p
g/
m
L)
Me
dia IL-
4
α−
CD
40LP
S
α−
μ
α−
CD
40
+ I
L-4
Cp
G
+/+
fl/+
fl/fl
A
B
C
D
E
Figure 3. Hyperresponsiveness of A20-Deficient
B Cells
In vitro responses of purified B cells after stimulation with the
indicated stimuli for 72 hr. Flow cytometric analyses of (A)
surface expression of the activation marker CD80 (B7.1) and
(B) dilution of CFSE-labeled cells. Tnfaip3fl/fl CD19-Cre (red
lines), Tnfaip3fl/+ CD19-Cre (blue lines), and Tnfaip3+/+
CD19-Cre (shaded gray) histograms are shown. In (C), ELISA
determination of IL-6 secretion in the supernatants of 72 hr B
cell cultures is shown. Means and standard deviations (SD) of
triplicate wells are shown. (D) shows immunoblots of A20 and
actin protein expression in purified Rosa-ER-Cre+ B cells of
the indicated genotypes. Lysates were isolated after 72 hr
stimulation with the indicated ligands in the presence of
4-OH-T. As shown in (E), expression of CD80 in purified B cells
after treatment with 4-OH-T and the indicated ligands for 72 hr.
Tnfaip3fl/fl GT-Rosa-Cre+ B cells treated with IL-4 or media
(black lines) or the indicated ligands (red lines) and Tnfaip3fl/+
GT-Rosa-Cre+ B cells treated with IL-4 or media (gray shaded
histograms) or the indicated ligands (blue lines) are shown. All
data are representative of three independent experiments.
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A20 Restricts B Cell Survivalincreased and prolonged canonical NF-kB signaling as
measured by IkBa phosphorylation in response to anti-CD40
(Figure 4B). Agonist anti-CD40 also induced greater amounts
of phospho-p100, an indicator of noncanonical NF-kB signaling,
in Tnfaip3fl/fl CD19-Cre B cells when compared to Tnfaip3+/+
CD19-Cre B cells (Figure 4C). This increased noncanonical
NF-kB signaling correlates with increased basal p100 protein
amounts in Tnfaip3fl/fl CD19-Cre B cells (Figure 4C). By contrast,
Erk phosphorylation was similarly induced in Tnfaip3fl/fl CD19-
Cre and control B cells (Figure 4D).
Normal Antigen-Specific B Cell Responses in Tnfaip3fl/fl
CD19-Cre Mice
A20s capacity to restrict B cell activation in vitro suggests that
Tnfaip3fl/fl CD19-Cre mice might exhibit exaggerated antigen-
specific B cell responses in vivo. We thus tested antigen-specific
B cell responses to NP-KLH in thesemice. At baseline, Tnfaip3fl/fl
CD19-Cremice have more IgM and modestly elevated amounts
of IgGs (Figure S2A). Tnfaip3fl/fl CD19-Cre mice produced pro-
portionately higher amount of anti-NP IgM antibodies beforeImmunity 3and after immunization with NP-KLH (Figure S2B).
All genotypes of mice generated similar amounts
of anti-NP IgG (Figure S2C). Thus, T cell-dependent
B cell responses occur largely normally in
Tnfaip3fl/fl CD19-Cre mice. Anti-NP-Ficoll IgM
responses paralleled T cell dependent NP-KLH
responses in Tnfaip3fl/fl CD19-Cre mice, indicating
that T cell-independent B cell responses also occur
normally in these mice (data not shown).
Tnfaip3fl/fl CD19-Cre and Tnfaip3fl/+ CD19-
Cre Mice Develop Autoimmunity
Increased numbers of immature and germinal
center B cells suggest that autoreactive B cells
may accumulate and produce autoantibodies in
Tnfaip3fl/fl CD19-Cre mice. In addition, several
SNPs near the human A20 (TNFAIP3) gene areindependently associated with susceptibility to SLE (Graham
et al., 2008; Musone et al., 2008). To characterize the autoanti-
body profile of Tnfaip3fl/+ CD19-Cre mice and Tnfaip3fl/fl CD19-
Cre mice as compared to Tnfaip3+/+ CD19-Cre mice, we used
large-scale 1152 feature protein and peptide microarrays to
detect autoantibodies directed against over 140 antigens
(Robinson et al., 2002). Antibodies to over 46 self-antigens
were detected, including antibodies to nuclear antigens (e.g.,
single-stranded DNA, small ribonuclear proteins A and C, and
Ku protein), glomerular antigens (e.g., vimentin, collagen X, pro-
teogylcan, and aggrecan), and heat-shock proteins (Figure 5A).
Importantly, the serum autoantibody profiles from Tnfaip3fl/fl
CD19-Cre and Tnfaip3fl/+ CD19-Cre mice clustered well with
each other and away from Tnfaip3+/+CD19-Cremice (Figure 5A).
These autoantibodies were observed in both male and female
mice and were observed in C57BL/6 inbred mice, a strain that
is relatively resistant to SLE-like disease. Elispot analysis for
anti-DNA indicate both an increase in the number and size of
anti-DNA producing B cells in Tnfaip3fl/fl CD19-Cre mice
(Figure 5B and data not shown). These findings indicate that3, 181–191, August 27, 2010 ª2010 Elsevier Inc. 185
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Figure 4. A20 Restricts NF-kB Signaling
Downstream of CD40 Signals
(A) Immunoblot analysis of A20 protein induction
by agonist anti-CD40.
(B) Immunoblot analyses of phospho-IkBa and
IkBa after CD40 stimulation. Ratios of pIkBa/
IkBa were normalized to time 0 of Tnfaip3+/+
CD19-Cre cells and are shown below.
(C) Immunoblot analyses of NF-kB P-p100 (upper
panel) and p100 (middle panel) protein amounts
in response to agonist CD40 antibody. Ratios of
P-p100/actin, normalized to time 0 sample in
Tnfaip3+/+ CD19-Cre B cells, are shown below
P-p100 immunoblot. Ratios of p100/actin, normal-
ized to time 0 sample in Tnfaip3+/+ CD19-Cre
B cells, are shown below p100 immunoblot.
(D) Immunoblot analysis of Erk signaling. Ratios of
pErk/Erk were normalized to time 0 of Tnfaip3+/+
CD19-Cre cells and are shown below. Actin
protein amounts shown below all panels as
loading controls. Data are representative of three
independent experiments.
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A20 Restricts B Cell SurvivalA20 expression in B cells prevents spontaneous production of
autoantibodies.
Autoantibodies can be deposited in glomeruli of kidneys of
SLE patients and ultimately cause glomerulonephritis. To deter-
mine whether serum autoantibodies in Tnfaip3fl/fl CD19-Cre and
Tnfaip3fl/+ CD19-Cre mice lead to glomerular Ig deposits, we
examined kidneys from 6-month-old mice by histology and
immunofluorescence. Although kidney sections appeared histo-
logically normal, IgM deposits were observed in the kidneys of
both Tnfaip3fl/fl CD19-Cre and Tnfaip3fl/+ CD19-Cre mice
(Figure 5C). IgG deposits were more prominent in Tnfaip3fl/+
CD19-Cre mice (Figure 5C).
In addition to autoantibody-producing B cells ‘‘escaping’’ from
negative selection, activation of innate immune cells and type I
interferon (IFN I) secretion may be key factors contributing to
autoantibody production and the pathogenesis of SLE (Fairhurst
et al., 2006; Shlomchik, 2008). CpG triggers B cell activation and
production of type I interferons (IFNs), and increases class
switching to pathogenic autoantibody isotypes (Ehlers et al.,
2006). We thus asked whether Tnfaip3fl/+ CD19-Cre and
Tnfaip3fl/fl CD19-Cre mice develop more autoimmune disease
after stimulation with CpG. CpG treatment of intact mice
enhanced production of IgG dsDNA antibodies in serum as
well as pathogenic deposition of IgG in renal glomeruli of both
Tnfaip3fl/fl CD19-Cre and Tnfaip3fl/+ CD19-Cre mice but not
Tnfaip3+/+ CD19-Cre mice (Figure 5D and data not shown).
Taken together, these findings indicate that A20 expression in
B cells prevents autoimmunity.
A20 Restricts B Cell Survival to Fas-Mediated PCD
Tnfaip3fl/+CD19-Cremice share two key features with Tnfaip3fl/fl
CD19-Cremice: increased numbers of GC B cells and suscepti-
bility to autoimmunity. These observations suggest that the186 Immunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc.amount of A20 expression regulates B cell selection in germinal
centers. One possible mechanism for negative selection of
autoreactive B cells in GCs is Fas-induced PCD (Hao et al.,
2008). We thus tested the susceptibility of Tnfaip3+/+ CD19-
Cre, Tnfaip3fl/+ CD19-Cre, and Tnfaip3fl/fl CD19-Cre B cells to
Fas-induced PCD. Splenic B cells were activated with agonist
anti-CD40 to induce Fas sensitivity. As expected, activation of
Tnfaip3+/+ CD19-Cre B cells caused increased expression of
Fas and dose-dependent sensitivity to Fas-mediated PCD
(Figures 6A and 6B). Tnfaip3fl/fl CD19-Cre B cells expressed
higher amounts of surface Fas than Tnfaip3+/+ CD19-Cre B cells
after CD40 stimulation, while Tnfaip3fl/+ CD19-Cre B cells
expressed intermediate amounts (Figure 6A). Remarkably,
Tnfaip3fl/fl CD19-Cre and Tnfaip3fl/+ CD19-Cre B cells were
resistant to Fas-mediated PCD when compared to control
Tnfaip3+/+ CD19-Cre cells—even though Tnfaip3fl/fl CD19-Cre
and Tnfaip3fl/+ CD19-Cre B cells expressed greater amounts of
Fas (Figure 6B). This finding is particularly surprising given our
prior observation that A20-deficient fibroblasts are more
susceptible to TNF-induced PCD than normal cells (Lee et al.,
2000). Thus, A20 supports Fas-mediated PCD in B cells and
inhibits TNFR-induced PCD in fibroblasts.
To understand why A20-deficient B cells are resistant to
Fas mediated PCD, we hypothesized that increased NF-kB
signaling in these cellsmight lead to increased expression of anti-
apoptotic proteins such as Bcl-x. After stimulation with agonist
anti-CD40 in vitro, Bcl-x mRNA expression increased within
1 hr and rose to a higher amount in Tnfaip3fl/fl CD19-Cre B cells
compared with Tnfaip3fl/+ CD19-Cre or Tnfaip3+/+ CD19-Cre B
cells (Figure 6C). CD40 triggered induction of Bcl-x mRNA was
blocked by the NF-kB inhibitor, NEMO-binding domain (NBD)
peptide, but not by control peptide (Figure 6C). Hence, NF-kB
signaling appears directly required for induced Bcl-x mRNA
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Figure 5. Spontaneous Autoantibody Production in Tnfaip3fl/+ CD19-Cre and Tnfaip3fl/fl CD19-Cre Mice
(A) Protein array analyses of autoantibodies in sera from 3 month old Tnfaip3fl/fl CD19-Cre (n = 5), Tnfaip3fl/+ CD19-Cre (n = 3), and Tnfaip3+/+ CD19-Cre (n = 4)
mice. Heat map shows relative reactivity to the respective antigens on the arrays, hierarchically clustered in both axes by Euclidean distance. The reactivity inten-
sities (MFI) are depicted on a relative color scale. Statistically different antigens were identified with two-class significant analysis of microarrays (SAMs) with an
unpaired t test.
(B) Antibody-forming cells (AFCs) measured by Elispot for anti-dsDNA Ig-producing B cells. Counts were plotted as the mean of triplicate wells and SD is shown.
Data are representative of three independent experiments.
(C) Immunofluorescent analyses of glomerular Ig deposition in 6-month-old mice of indicated genotypes. Analyses of IgM and IgG deposits shown in upper and
middle panels, respectively. Data are representative of at least three mice per genotype.
(D) Immunofluorescent analyses of glomerular deposition of Igs of the indicated isotypes after CpG treatment. Eight to ten-week-old mice (n = 4) of the indicated
genotypes were treated with 40 mg of CpG intraperitoneally every other day for 2 weeks. Mice were analyzed 6 weeks after start of treatment. Hematoxlin and
eosin (H&E) sections are shown above, and all sections are shown at 1003 the original magnification (C and D).
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A20 Restricts B Cell Survivaltranscription.Consistentwith enhancedBcl-xmRNAexpression,
markedly higher quantities of Bcl-x protein appear in Tnfaip3fl/fl
CD19-Cre B cells compared with Tnfaip3fl/+ CD19-Cre or
Tnfaip3+/+ CD19-Cre B cells (Figure 6D). Taken together, these
findings indicate that A20 restricts the survival of activatedBcells
by limiting the NF-kB-dependent transcription of Bcl-x mRNA
and the subsequent production of Bcl-x protein. They also
provide a potential mechanism by which A20 deficient B cells
are resistant to negative selection in germinal centers.
DISCUSSION
The generation and characterization of mice lacking A20 specif-
ically in B cells, Tnfaip3fl/fl CD19-Cre mice, has allowed us tounveil several functions for A20. We have discovered that B
cell-specific expression of A20 restricts CD40 and BCR
responses, terminates CD40-triggered NF-kB signals, restricts
B cell survival, and prevents autoimmunity. These studies
provide unique molecular insights into B cell homeostasis,
human SLE and B cell lymphomas.
Tnfaip3fl/fl CD19-Cre mice are largely healthy, in marked
contrast to mice lacking A20 expression in all cells or in all hema-
topoietic cells. This observation is consistent with our prior
suggestion that the cachexia, myeloid dysregulation, and peri-
natal lethality observed in globally A20-deficient mice is largely
due to myeloid cell dysfunction. Although Tnfaip3fl/fl CD19-Cre
mice contained mild expansion of T cell numbers, these pertur-
bations are probably not due to aberrant A20 deletion as judgedImmunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc. 187
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Figure 6. A20-Deficient and Hypomorphic B Cells Are
Resistant to Programmed Cell Death
(A) Flow cytometric analyses of CD95 (Fas) expression in en-
riched B cells after agonist anti-CD40 stimulation. Overlays
of CD95 histograms on gated CD19+ cells from Tnfaip3+/+
CD19-Cre (shaded), Tnfaip3fl/+ CD19-Cre (dashed line),
Tnfaip3fl/flCD19-Cre (black line), and unstained control (dotted
line) are shown.
(B) Enriched B cells stimulated for 48 hr with agonist anti-CD40
and treated with the indicated concentrations of agonist
anti-CD95 for 12 hr were analyzed for survival by measuring
the percentage of dead (Annexin-V+ DAPI+) cells by flow
cytometry. Percent death was calculated as ([% Fas-induced
dead  % control dead]/[100%  % control dead]). Data are
plotted as mean ± SD of triplicate wells. The asterisk indicates
p < 0.001 with two-way ANOVA. The asterisk indicates
p < 0.05 in comparison with +/+ samples by Student’s t test.
(C) Bcl-x mRNA amounts measured by real-time quantitative
(RT qPCR) in enriched B cells. Cells of the indicated genotypes
were stimulated with agonist anti-CD40 for the indicated times
in the presence of an inhibitor (NBD) or a control peptide, or left
unstimulated. Data are plotted asmean ± SD of triplicate wells.
p < 0.001 with two-way ANOVA; the asterisk indicates p < 0.05
in comparison with +/+ samples by Student’s t test.
(D) Immunoblot analysis for the expression of Bcl-x protein in
B cells of the indicated genotypes stimulated with agonist
anti-CD40 for the indicated times. Actin protein amounts are
shown below as a control. Ratios of Bcl-x to actin protein,
normalized to the Tnfaip3+/+ B cells at time 0, are shown below
each sample. All data are representative of three independent
experiments.
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A20 Restricts B Cell Survivalby our molecular analyses and by the published literature for this
Cre strain (Rickert et al., 1997; Schmidt-Supprian and Rajewsky,
2007). Rather, these mice express increased quantities of
splenic IL-4 mRNA (data not shown), and Tnfaip3fl/fl CD19-Cre
B cells produced more IL-6 and expressed higher amounts of
costimulatory molecules upon stimulation. Thus, T cell expan-
sion may be due to antigen-independent bystander effects
induced by B cell-derived cytokines and/or costimulatory mole-
cules, as has been observed in other settings of B cell hyperres-
ponsiveness (Ho¨mig-Ho¨lzel et al., 2008; Hao et al., 2008).
Our findings demonstrate that A20 performs important func-
tions in adaptive immune cells in addition to previously
described functions in innate immune cells (Lee et al., 2000;
Boone et al., 2004; Hitotsumatsu et al., 2008). A20’s roles in re-
stricting CD40- and BCR-triggered NF-kB signals add to the
spectrum of signaling cascades regulated by this ubiquitin modi-
fying enzyme. NF-kB signaling is important for regulating B cell
homeostasis (Sen, 2006; Siebenlist et al., 2005). The phenotypes
of our mice lacking A20 expression in B cells reveal the impor-
tance of tightly regulating basal NF-kB signals in these cells.
B cell-specific loss of A20 expression leads to increased
numbers of autoantibody-producing cells. B cells undergo
several stages of negative selection to eliminate autoreactive
cells both in the bone marrow and in peripheral lymphoid organs188 Immunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc.(Jacobi and Diamond, 2005; Shlomchik, 2008;
Yurasov and Nussenzweig, 2007; von Boehmer
andMelchers, 2010). In the bonemarrow, immature
B cells are selected as a consequence of BCR and
BAFF signals and intracellular cell survival factors.In the periphery, selection occurs during GC maturation.
Germinal centers are sites where B cells undergo expansion,
immunoglobulin class switching, somatic hypermutation, and
affinity maturation (Klein and Dalla-Favera, 2008). B cells with
lowaffinity for antigen or reactivity for self-antigens are negatively
selected within GCs (Shlomchik, 2008). Deletion of autoreactive
B cells helps prevent autoimmunity, and defective GC selection
of autoreactive B cells has been observed in human SLE patients
(Cappione et al., 2005). Fas (CD95) is highly expressed on GC B
cells (Watanabe et al., 1995). Although the role of Fas-mediated
PCD in GC selection has been controversial (Smith et al., 1995;
Takahashi et al., 2001; Mizuno et al., 2003; Hao et al., 2008),
FasmediatedPCD likely plays an important role in eliminating au-
toreactive B cells (Rathmell et al., 1995; Fukuyama et al., 2002;
William et al., 2002). Thus, the accumulation of GC B cells in
Tnfaip3fl/+ CD19-Cre and Tnfaip3fl/fl CD19-Cre mice may be
due to the increased resistance of A20-deficient B cells to phys-
iological PCD, leading to the escape of autoreactive B cells.
How might A20 deficiency in B cells render them resistant to
PCD? One possibility stems from the observation that NF-kB-
dependent proteins protect B cells against PCD. Indeed, both
canonical and noncanonical NF-kB signaling downstream of
BCR, CD40, BAFF, and TLR receptors are thought to promote
B cell survival as well as proliferation and activation (Siebenlist
Immunity
A20 Restricts B Cell Survivalet al., 2005; Sen, 2006; Ho¨mig-Ho¨lzel et al., 2008). NF-kB has
been suggested to be necessary for mediating BCR-induced
resistance to Fas-mediated PCD (Mizuno et al., 2003; Schram
and Rothstein, 2003). Our studies indicate that A20 directly
restricts canonical NF-kB signals and suggest that these signals
may lead to elevated noncanonical NF-kB signals. These
increased NF-kB signals lead to increased expression of antia-
poptotic proteins such as Bcl-2 and Bcl-x. Deregulated expres-
sion of these proteins has been shown to cause altered GCB cell
selection (Grillot et al., 1996; Takahashi et al., 1999). Hence,
increased expression of Bcl-x and/or other NF-kB-dependent
proteins may provide a molecular underpinning for increased
numbers of GC B cells in Tnfaip3fl/fl CD19-Cre mice.
Heterozygous Tnfaip3fl/+ CD19-Cre mice contain similarly
increased numbers of GCBcells and autoantibodies as homozy-
gous Tnfaip3fl/fl CD19-Cre mice at young ages (i.e., 5–7 weeks
old), suggesting that a high threshold of A20 expression must
be maintained for properly selecting (or deleting) these cells.
Reduced A20 expression in other cell types leads to increased
production of NF-kB-dependent gene products, so endogenous
amounts of A20 protein appear to be limiting (A.M., unpublished
data). Reduced (rather than absent) quantities of A20 expression
or hypomorphic A20 proteins may also link A20 (TNFAIP3)
susceptibility SNPs with SLE in human patients (Musone et al.,
2008). Thus,miceexpressing reducedamountsofA20mayprove
to be highly relevant models of human autoimmune diseases.
Although reduced A20 expression in B cells leads to accumu-
lation of GC B cells and IgG autoantibodies, absent A20 expres-
sion also causes accumulation of immature B cells and IgM in
Tnfaip3fl/fl CD19-Cre mice and progressive activation of B cells
with age. Hence, a lower amount of A20 is necessary to preserve
selection of immature B cells and to restrict spontaneous B cell
activation than the amount required for proper GC selection. As
IgM autoantibodies may be protective against IgG-mediated
autoimmune disease, higher IgM amounts in homozygous
Tnfaip3fl/fl CD19-Cre mice may reduce the degree of autoim-
mune disease observed in these mice (Witte, 2008). A20
amounts are dynamically regulated, largely in response to NF-
kB signals (Krikos et al., 1992). Thus, A20 expression amounts
appear to be finely tuned to regulate NF-kB signaling and
survival of distinct subsets of B cells.
Tnfaip3fl/fl CD19-Cre mice exhibit largely normal antigen
specific B cell responses in vivo, despite the fact that mature
Tnfaip3fl/fl CD19-Cre B cells exhibit increased responses to
BCR, CD40, and TLR ligands in vitro. These findings suggest
that B cell-independent factors such as T cells and myeloid cells
can properly restrict antigen-specific B cell responses, even if
they allow progressive accumulation of autoreactive B cells in
Tnfaip3fl/fl CD19-Cre mice.
Our experiments indicate that A20 expression in B cells regu-
lates GC B cell selection as well as B cell activation, thereby
regulating key aspects of B cell tolerance. It is remarkable that
B cell-specific deletion of A20 alone is sufficient for autoimmu-
nity in C57BL/6 mice. The appearance of IgG deposits suggests
that abnormal B cells are sufficient for at least the initial stages of
the autoimmunity and are part of the continuum to full-blown
disease. Hence, lupus-prone Tnfaip3fl/fl CD19-Cre and
Tnfaip3fl/+ CD19-Cremice as well as genetic derivatives of these
mice should be useful models for understanding human SLE.Heterozygous Tnfaip3fl/+ CD19-Cre mice may be particularly
relevant, as reduced, rather than absent A20 expression may
characterize this human condition.
Recent studies have shown that somatic loss of A20 in B cells
causes several types of Hodgkin, non-Hodgkin, and marginal
zone B cell lymphomas in humans (Kato et al., 2009; Compagno
et al., 2009; Schmitz et al., 2009; Novak et al., 2009). Our findings
that A20-deficient B cells express high amounts of Bcl-x and are
resistant to Fas-mediated PCD provide molecular insights into
howA20 functions as a tumor suppressor in B cells. Remarkably,
A20 is a proapoptotic protein in B cells even though it restricts
TNF-induced apoptosis in fibroblasts and hepatocytes (Lee
et al., 2000; Arvelo et al., 2002). Hence, it is critical to analyze
A20’s physiological functions in cell type-specific contexts.
Future studies testing the potential of A20 deficiency to collabo-
rate with other B cell oncogenes may reveal the spectrum of
A20’s tumor suppressor functions in B cells.
In conclusion, we have demonstrated functions for A20 in regu-
lating B cell responses, including the restriction of CD40-induced
NF-kB signals. These cell-autonomous functions are critical for B
cell homeostasis and the prevention of autoreactive B cells and
autoimmunity. In addition tounveiling newmolecularmechanisms
of B cell homeostasis, these studies provide critical insights into
the pathogenesis of human SLE and B cell lymphomas.EXPERIMENTAL PROCEDURES
Generation of A20 Conditionally Targeted (Tnfaip3fl/fl) Mice
Recombineering was used for generating a gene targeting construct from
a bacterial artificial chromosome (BAC) from the C57BL/6J strain containing
the tnfaip3 gene. C57BL/6 ESCs (PRX-B6T, Primogenix) were transfected
with this construct, and successfully targeted ESCs were identified by
Southern blot analysis. Correctly targeted clones were then transfected with
recombinant Cre and screened for removal of the neomycin cassette for ob-
taining the tnfaip3 ‘‘floxed’’ allele. Blastocyst injections of targeted ESCs
were performed by the UCSF Transgenic Core. Chimeras were bred to albino
C57BL/6J mice and nonalbino progeny were screened for the presence of the
floxed allele (Tnfaip3fl/+). Mice bearing the targeted allele in the germline were
interbred with CD19-Cre mice on the C57BL/6 background (B6.129P2(C)-
CD19tm1(cre)Cgn/J) (Rickert et al., 1997). Tnfaip3fl/fl or Tnfaip3 fl/+ mice homozy-
gous for CD19-Cre were bred with Tnfaip3fl/fl or Tnfaip3 fl/+ mice without the
CD19-Cre allele for generating experimental mice of various Tnfaip3 geno-
types (Tnfaip3+/+, Tnfaip3fl/+ and Tnfaip3fl/fl) that have one copy of Cre and
are heterozygous for CD19. Genotypes were initially confirmed by Southern
blot analysis and subsequently identified by PCR with the following primers:
50-AACTTTACAGTCCCCAGCAATGG-30 (sense); and 50-GAGGAGGTTGGAA
GACATAGAATCG-30 (antisense).Cell Preparation and Analyses
Single-cell suspensions were prepared and incubated with the designated
conjugated antibodies (all from BD Biosciences, except anti-CD5 and anti-
CD93 [AA4.1], eBioscience), and live cells (DAPI) were analyzed by flow
cytometry (LSRII, BD Biosciences) with FlowJo software (Tree Star). BMDMs
were prepared as previously described (Boone et al., 2004). For in vitro assays,
B cells were isolated by negative depletion with TCRb, Mac-1, NK1.1 and
Ter119 biotinylated antibodies (BD Biosciences) bound to streptavidin coated
magnetic beads (M-280 Dynabeads, Invitrogen). Cells were stimulated with
anti-CD40 (HM40-3, BD Biosciences) at 1 mg/ml, anti-m chain (Jackson
Immunoresearch) at 2 mg/ml, IL-4 (Peprotech) at 10 ng/ml, and LPS (Sigma)
at 1 mg/ml. For in vitro deletion of tnfaip3 exon 2 fromGT-RosaCre B cells, cells
were treated with 4-OH-T (2.5 nM) for the first 12 hr of stimulation. For NF-kB
inhibition, control peptide or NBD Peptide (Calbiochem) was added at 0.5 mM
1 hr prior to stimulation with agonist CD40 antibody.Immunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc. 189
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For in vivo antigen responses, 6- to 8-week-old mice were injected intraperito-
neally (i.p.) and bled on the indicated days. Mice were injected with 50 mg NP-
KLH (Biosearch Technologies) mixed 1:1 with Imject Alum (Thermo Scientific).
For CpG treatment, 8-week-old mice were injected i.p., every other day for
2 weeks, with 40 mg CpG ODN 2395 (tcgtcgttttcggcgcgcgccg) with phosphor-
othioate bases (Invitrogen). Serum was collected before treatment, and
6 weeks after treatment. All animal experiments were approved by the Institu-
tional Animal Care and Use Committee at the University of California, San
Francisco.
Immunoglobulin and AFC Determination
Quantities of serum and supernatant immunoglobulins (total Ig, IgM, IgG1,
IgG2c, IgG2b, IgG3, and IgA) were determined by isotype specific ELISA
(Southern Biotechnology). NP (4-Hydroxy-3-nitrophenylacetyl) -specific anti-
body titers were determined by ELISA with plates coated with NP23-BSA (Bio-
search Technologies). dsDNA-specific antibody titers were determined by
ELISA with plates coated with Hind III (New England Biolabs) digested
pUC19 in 0.1M Tris, overnight at room temperature. Cytokines amounts
were measured by ELISA as recommended by the manufacturer (BD Biosci-
ences). Elispot was performed by incubating enriched B cells on plates coated
with dsDNA as above. After overnight incubation, plates were washed and
incubated with alkaline phosphatase (AP) conjugated anti-IgM (Southern
Biotech) and subsequently developed with BCIP substrate (Sigma) dissolved
into alkaline phosphatase buffer (0.1M Tris, 0.1 M NaCl, and 5 mM MgCl2)
and 0.6% LMP Agarose (Sigma).
Autoantigen arrays were printed and processed as previously described.
Arrays were probed with goat antibody specific for mouse Ig (Jackson Immu-
noresearch). Detailed protocols and lists of antigens have been published and
are available online at http://utzlab.stanford.edu/protocols (Robinson et al.,
2002). Significance analysis of microarrays (SAM) was applied to the data
for identification of antigens with statistically significant differences in array
reactivity between mutant and wild-type mice (Tusher et al., 2001).
Histology and Immunohistochemistry
Kidneys and spleens were fixed in 10% formalin. Sections and H&E stain were
performed by the UCSF VAMC Pathology Core. For immunohistochemistry,
kidneys were embedded in Tissue-Tek OCT compound and snap frozen in
methyl-butane with dry ice. Tissue sections were then stained with IgM-FITC
or IgG-FITC (Jackson Immunoresearch) or with IgG2c-FITC or IgG2b-FITC
(Bethyl Laborotories).
Cell Signaling Assays
Enriched B cells were stimulated as indicated in the figures and lysed in 0.1%
NP-40 (Calbiochem) lysis buffer, and nuclei were spun down so that cyto-
plasmic lysates were produced. Lysates were cleared by centrifugation at
14,000 g for 20 min at 4C, supernatants were removed, heated in Laemmli
buffer and run on SDS-PAGE (Novex System, Invitrogen). Immunoblots were
probed for A20 (Boone et al., 2004), actin (JLA20, Calbiochem), phospho-
IkBa, IkBa, phospho-Erk, Erk, phospho-NF-kB2 p100 and NF-kB2 p100/p52
(Cell Signaling), and Bcl-x (Transduction Biotechnologies).
Fas-Induced Cell Death Assay
Fas-induced cell death assays were performed as described (Watanabe et al.,
1995; Wang et al., 1996). In brief, enriched B cells were plated with agonist
anti-CD40 (1 mg/ml) for 60 hr. Agonist anti-CD95 (Fas) was added to the
cultures at the indicated doses for the last 12 hr. Cells were harvested and
stained for flow cytometry with Annexin-V (BD Biosciences) and DAPI.
Real-Time PCR Assays
For quantitation of genomic Tnfaip3 exon 2, DNA was prepared with the
DNeasy Kit (QIAGEN), after which qPCR was performed with SYBR Green
(QIAGEN). Primers for exon 2 of Tnfaip3 were the following: 50-
CTGACCTGGTCCTGAGGAAG-30 (sense); and 50-GCAAAGTCCTGTTTCCA
CAA-30 (anti-sense). This qPCR assay was shown to detect less than 1% of
exon 2 DNA in titrated mixtures of Tnfaip3/ and Tnfaip3+/+ cells (data not
shown). For quantitation of Bcl-x mRNA expression, mRNA was prepared
with RNeasy Kit (QIAGEN) and cDNA was obtained with Quantitect Reverse190 Immunity 33, 181–191, August 27, 2010 ª2010 Elsevier Inc.Transcription Kit (QIAGEN). Primers for Bcl-x cDNA were the following: 50-
GCAGACCCAGTAAGTGAGCA-30 (sense) and 50-AGAAAGTCGACCACCAG
CTC-30 (antisense). In both types of assays, b-actin primers used as a refer-
ence were: 50- AAGTGTGACGTTGACATCCGTAA-30 (sense) and 50-TGCC
TGGGTACATGGTGG TA-30 (antisense). Assays were performed with an ABI
7300 real-time PCR machine (Applied Biosystems).
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at doi:10.1016/j.immuni.2010.07.017.
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